Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies

Area of Science:

• Biochemistry
• Structural Biology
• Cancer Research

Background:

• The EPHA2 receptor tyrosine kinase is overexpressed in several cancers, making its kinase domain (KD) a target for therapeutic intervention.
• Obtaining pure, homogeneous EPHA2 KD protein is crucial for structural studies and drug discovery but has been challenging.
• Small-molecule inhibitors targeting the EPHA2 KD are a promising therapeutic strategy.

Purpose of the Study:

• To develop a method for producing pure and homogeneous EPHA2 kinase domain (KD) protein suitable for structural studies.
• To obtain novel crystal structures of EPHA2-ligand complexes for drug discovery.
• To establish a strategy for isotopic labeling of EPHA2 KD for NMR-based investigations.

Main Methods:

• Expression and purification of different EPHA2 KD fragments in bacterial (E. coli) and insect (Sf9) cells.
• Assessment of protein folding and homogeneity using 1H, 15N HSQC.
• Crystallization of the EPHA2 KD construct (D596-G900) produced in Sf9 cells.
• Determination of eleven new EPHA2-ligand crystal structures.
• Development of a strategy for selective 15N-amino acid labeling in Sf9 cells.

Main Results:

• E. coli-expressed EPHA2 KD was well-folded but unstable and did not crystallize.
• An EPHA2 KD construct (D596-G900) expressed in Sf9 cells yielded homogenous, well-folded protein that readily crystallized.
• Eleven new EPHA2-ligand crystal structures were obtained.
• A strategy for uniform 15N-amino acid labeling of EPHA2 KD in Sf9 cells was established.

Conclusions:

• Insect cell expression is a viable strategy for producing stable, crystallizable EPHA2 KD protein.
• The newly determined crystal structures provide valuable insights for EPHA2-targeted drug discovery.
• The established labeling strategy enables further investigation of EPHA2 dynamics and drug interactions using NMR.